These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 2909524)

  • 1. A new folate antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolate is a potent inhibitor of de novo purine synthesis.
    Beardsley GP; Moroson BA; Taylor EC; Moran RG
    J Biol Chem; 1989 Jan; 264(1):328-33. PubMed ID: 2909524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The 6S- and 6R-diastereomers of 5, 10-dideaza-5, 6, 7, 8-tetrahydrofolate are equiactive inhibitors of de novo purine synthesis.
    Moran RG; Baldwin SW; Taylor EC; Shih C
    J Biol Chem; 1989 Dec; 264(35):21047-51. PubMed ID: 2592365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (6R)-5,10-Dideaza-5,6,7,8-tetrahydrofolic acid effects on nucleotide metabolism in CCRF-CEM human T-lymphoblast leukemia cells.
    Pizzorno G; Moroson BA; Cashmore AR; Beardsley GP
    Cancer Res; 1991 May; 51(9):2291-5. PubMed ID: 1707749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multifactorial resistance to 5,10-dideazatetrahydrofolic acid in cell lines derived from human lymphoblastic leukemia CCRF-CEM.
    Pizzorno G; Moroson BA; Cashmore AR; Russello O; Mayer JR; Galivan J; Bunni MA; Priest DG; Beardsley GP
    Cancer Res; 1995 Feb; 55(3):566-73. PubMed ID: 7834626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determinants of the disparate antitumor activities of (6R)-5,10-dideaza-5,6,7,8-tetrahydrofolate and methotrexate toward human lymphoblastic leukemia cells, characterized by severely impaired antifolate membrane transport.
    Matherly LH; Angeles SM; McGuire JJ
    Biochem Pharmacol; 1993 Dec; 46(12):2185-95. PubMed ID: 7506026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracellular metabolism of 5,10-dideazatetrahydrofolic acid in human leukemia cell lines.
    Pizzorno G; Sokoloski JA; Cashmore AR; Moroson BA; Cross AD; Beardsley GP
    Mol Pharmacol; 1991 Jan; 39(1):85-9. PubMed ID: 1702876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for a relationship between intracellular GTP levels and the induction of HL-60 leukemia cell differentiation by 5,10-dideazatetrahydrofolic acid (DDATHF).
    Sokoloski JA; Pizzorno G; Beardsley GP; Sartorelli AC
    Oncol Res; 1993; 5(8):293-9. PubMed ID: 8012061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis.
    Mauritz R; Peters GJ; Priest DG; Assaraf YG; Drori S; Kathmann I; Noordhuis P; Bunni MA; Rosowsky A; Schornagel JH; Pinedo HM; Jansen G
    Biochem Pharmacol; 2002 Jan; 63(2):105-15. PubMed ID: 11841783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of HL-60 leukemia cell differentiation by tetrahydrofolate inhibitors of de novo purine nucleotide biosynthesis.
    Sokoloski JA; Beardsley GP; Sartorelli AC
    Cancer Chemother Pharmacol; 1991; 28(1):39-44. PubMed ID: 2040032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of HL-60 leukemia cell differentiation by the novel antifolate 5,10-dideazatetrahydrofolic acid.
    Sokoloski JA; Beardsley GP; Sartorelli AC
    Cancer Res; 1989 Sep; 49(17):4824-8. PubMed ID: 2758415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The stereospecific cytotoxic potency of (6R) and (6S)-5,10- dideazatetrahydrofolate correlates with cellular folylpolyglutamate synthetase levels.
    Lehman NL
    Biochimie; 1995; 77(4):273-8. PubMed ID: 8589057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth-inhibitory effects of 5,10-dideazatetrahydrofolic acid on variant murine L1210 and human CCRF-CEM leukemia cells with different membrane-transport characteristics for (anti)folate compounds.
    Jansen G; Westerhof GR; Kathmann I; Rijksen G; Schornagel JH
    Cancer Chemother Pharmacol; 1991; 28(2):115-7. PubMed ID: 2060081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antifolates targeting purine synthesis allow entry of tumor cells into S phase regardless of p53 function.
    Bronder JL; Moran RG
    Cancer Res; 2002 Sep; 62(18):5236-41. PubMed ID: 12234990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitivity to 5,10-dideazatetrahydrofolate is fully conserved in a murine leukemia cell line highly resistant to methotrexate due to impaired transport mediated by the reduced folate carrier.
    Zhao R; Gao F; Babani S; Goldman ID
    Clin Cancer Res; 2000 Aug; 6(8):3304-11. PubMed ID: 10955817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5,10-Dideazatetrahydrofolic acid reduces toxicity and deoxyadenosine triphosphate pool, expansion in cultured L1210 cells treated with inhibitors of thymidylate synthase.
    Chong LK; Tattersall MH
    Biochem Pharmacol; 1995 Mar; 49(6):819-27. PubMed ID: 7702640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytotoxicity of antifolate inhibitors of thymidylate and purine synthesis to WiDr colonic carcinoma cells.
    Smith SG; Lehman NL; Moran RG
    Cancer Res; 1993 Dec; 53(23):5697-706. PubMed ID: 8242626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 10-Formyl-5,10-dideaza-acyclic-5,6,7,8-tetrahydrofolic acid (10-formyl-DDACTHF): a potent cytotoxic agent acting by selective inhibition of human GAR Tfase and the de novo purine biosynthetic pathway.
    Marsilje TH; Labroli MA; Hedrick MP; Jin Q; Desharnais J; Baker SJ; Gooljarsingh LT; Ramcharan J; Tavassoli A; Zhang Y; Wilson IA; Beardsley GP; Benkovic SJ; Boger DL
    Bioorg Med Chem; 2002 Aug; 10(8):2739-49. PubMed ID: 12057663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical studies on PT523, a potent nonpolyglutamatable antifolate, in cultured cells.
    Rhee MS; Galivan J; Wright JE; Rosowsky A
    Mol Pharmacol; 1994 Apr; 45(4):783-91. PubMed ID: 7514264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of (6R)-5,10-dideazatetrahydrofolate: a folate antimetabolite inhibitory to de novo purine synthesis.
    Ray MS; Muggia FM; Leichman CG; Grunberg SM; Nelson RL; Dyke RW; Moran RG
    J Natl Cancer Inst; 1993 Jul; 85(14):1154-9. PubMed ID: 8320744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of 2-desamino-2-methyl-10-propagyl-5,8-dideazafolic acid cytotoxicity by 5,10-dideazatetrahydrofolate in L1210 cells with decrease in DNA fragmentation and deoxyadenosine triphosphate pools.
    Kwok JB; Tattersall MH
    Biochem Pharmacol; 1991 Jul; 42(3):507-13. PubMed ID: 1859463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.